Evidence map›Paper›PMID 24648795›Full record

ReviewThe Korean journal of internal medicine2014

Newer treatments for advanced hepatocellular carcinoma.

Myeong Jun Song, Si Hyun Bae

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Korean journal of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Myeong Jun SongDivision of Hepatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.
Si Hyun BaeDivision of Hepatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options are needed for patients with advanced HCC. The current standard treatment for patients with advanced HCC, according to the Barcelona Clinic Liver Cancer staging system, is the multikinase inhibitor sorafenib. Other alternative therapies are required, due to the limited treatment response to, and tolerance of, this molecular target agent. Clinical trials of hepatic artery infusion chemotherapy, radioembolization, and multimodal treatments have shown favorable results in advanced HCC patients. This article introduces new treatment modalities for advanced HCC and discusses future therapeutic possibilities.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularCombined Modality TherapyEmbolization, TherapeuticHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsMolecular Targeted TherapyNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsRadiopharmaceuticalsSignal TransductionSorafenibTreatment OutcomeAntineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsRadiopharmaceuticalsSorafenibChemotherapyCombined modality therapyHepatocellular carcinomaRadiotherapySorafenib

Identifiers

PMID24648795
PMCPMC3956982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.